Compare › Ozempic vs Rybelsus
Ozempic vs Rybelsus
Ozempic and Rybelsus are the same molecule — semaglutide. They are sold under separate FDA applications (NDA209637, NDA213051 and NDA213051, NDA213182), which is why they carry different approved indications, different labels and different supply records. On the regulatory record they are distinct products with an identical active ingredient.
| Ozempic | Rybelsus | |
|---|---|---|
| Active ingredient | semaglutide | semaglutide |
| FDA application | NDA209637, NDA213051 | NDA213051, NDA213182 |
| First FDA action | 2017-12-05 | 2019-09-20 |
| Sponsor | Novo Nordisk | Novo Nordisk |
| EU authorisation | Ozempic | Rybelsus |
| FDA supply status | No open records | 3 to be discontinued |
| FDA actions on file | 29 | 14 |
| Active trials of the molecule | 214 | 214 |
Everything above is a field from Drugs@FDA, the FDA Drug Shortage Database, the EMA register or ClinicalTrials.gov. There is no efficacy comparison here and there will not be one: head-to-head claims belong to the trials that made them, and which drug suits a particular person is a question for a clinician.
Full records: Ozempic · Rybelsus · semaglutide